Lyell Immunopharma raised $175m in Series A financing led by BMGI Group.

Synopsis

Lyell Immunopharma, a biotechnology company in South San Francisco, raised $175m in Series A financing led by BMGI Group.

Principals

Lyell Immunopharma

Bmgi Group

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (1)

elizabeth homans

President at LYELL IMMUNOPHARMA

Manager

target

Deal

£ 137 M

Total Value

Bidder Team (1)

naresh raisinghani

CEO at BMGI GROUP

Manager

bidder

Deal

£ 137 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy